Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 12, 2013, Pages 2303-2310

  Mollee, Peter ^a,b   Tate, Jill ^c   Pretorius, Carel J ^c  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Pathology Queensland ^*  (Australia)

Author keywords

AL amyloidosis; Diagnosis; Free light chain assay; Monitoring

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MELPHALAN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; THALIDOMIDE;

AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOPSY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG MEGADOSE; ELECTROPHORESIS; FREE LIGHT CHAIN ASSAY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOLOGY TEST KIT; INTERMETHOD COMPARISON; LIGHT CHAIN; MAJOR CLINICAL STUDY; MOLECULAR CLONING; NEPHELOMETRY; OVERALL SURVIVAL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

AMYLOIDOSIS; CLINICAL CHEMISTRY TESTS; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; LATEX; SENSITIVITY AND SPECIFICITY;

EID: 84889603382     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0361     Document Type: Article

References (20)

1. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, et al. Outcome in systemic al amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122: 78-84.
2. Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009;55: 499-504.
3. Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009;55: 1517-22.
4. Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 2011;86: 251-5.
5. Morris KL, Tate JR, Gill D, Kennedy G, Wellwood J, Marlton P, et al. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. Intern Med J 2007;37: 456-63.
6. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107: 3854-8.
7. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23: 215-24.
8. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosis. Leukemia 2012;26: 2317-25.
9. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79: 319-28.
10. Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta 2007;376: 30-6.
11. Tate J, Bazeley S, Sykes S, Mollee P. Quantitative serum free light chain assay - analytical issues. Clin Biochem Rev 2009;30: 131-40.
12. Davern S, Tang LX, Williams TK, Macy SD, Wall JS, Weiss DT, et al. Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. Am J Clin Pathol 2008;130: 702-11.
13. te Velthuis H, Knop I, Stam P, van den Broek M, Bos HK, Hol S, et al. N latex FLC - new monoclonal high-performance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med 2011;49: 1323-32.
14. Pretorius CJ, Klingberg S, Tate J, Wilgen U, Ungerer JP. Evaluation of the N latex FLC free light chain assay on the siemens BN analyser: precision, agreement, linearity and variation between reagent lots. Ann Clin Biochem 2012;49: 450-5.
15. Mollee P, Tiley C, Cunningham I, Moore J, Prince HM, Cannell P, et al. A phase II study of risk-adapted intravenous melphalan in pati1.
16. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, et al. Outcome in systemic al amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122: 78-84.
17. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30: 4541-9.
18. Palladini G, Bosoni T, Milani P, Pirolini L, Foli A, Li Bergolis F, et al. Use of the novel monoclonal assay for the measurement of circulating free light chain in the diagnosis, prognostication of survival and assessment of response to therapy in AL amyloidosis. Blood 2012;120: 3913a.
19. Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood 2010;116: 5126-9.
20. Campbell JP, Cobbold M, Wang Y, Goodall M, Bonney SL, Chamba A, et al. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine. J Immunol Methods 2013;391: 1-13.